12:00 AM
 | 
May 14, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/11 cls
Acorda (ACOR) Lazard Joel Sendek Price target Buy -5% $23.97
Sendek raised his target to $30 from $28. He expects data from ACOR's second Phase III trial of Fampridine-SR to treat multiple sclerosis (MS) in 2Q08.
Advanced Life (ADLS) Lazard Matthew Osborne Price target Buy -12% $3.06
Osborne raised his target to $6 from $5. He expects Phase III data in June for cethromycin to treat community-acquired pneumonia, followed by a partnership and NDA submission in 4Q07.
Aeterna Zentaris (TSX:AEZ; AEZS) Dundee David Martin Rating change Under review (from market outperform) -11% $3.54
Martin's rating change came after Solvay (Euronext:SOLB) returned its remaining rights to AEZ's cetrorelix (see B2). Last year, SOLB returned its rights to the GnRH/LHRH receptor antagonist...

Read the full 815 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >